| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/17/2011 | US20110038875 Hematopoietic cells expressing the protein susd3 and ligands for the protein susd3 |
| 02/17/2011 | US20110038874 Anti-vegfr monoclonal antibody, method of making and uses thereof |
| 02/17/2011 | US20110038873 Means and methods for treating or preventing brain tumors based on the nuclear receptor tailless (tlx) |
| 02/17/2011 | US20110038872 Methods of diagnosing and treating autism |
| 02/17/2011 | US20110038871 Ccr2 inhibitors for treating conditions of the eye |
| 02/17/2011 | US20110038870 Compositions and methods to enhance the immune system |
| 02/17/2011 | US20110038869 Monoclonal antibodies against cd32b |
| 02/17/2011 | US20110038868 Il-17 homologous polypeptides and therapeutic uses thereof |
| 02/17/2011 | US20110038867 Remedies for pemphigus containing anti fas ligand antibodies |
| 02/17/2011 | US20110038866 Improved fibronectin-based binding molecules and uses thereof |
| 02/17/2011 | US20110038865 Antibody- endostatin fusion protein and its variants |
| 02/17/2011 | US20110038864 Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof |
| 02/17/2011 | US20110038863 Methods and compositions for improving recombinant protein production |
| 02/17/2011 | US20110038862 Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-postitive and her2-positive subtypes with clinical implications |
| 02/17/2011 | US20110038861 Methods of Treating Alzheimer's Disease Using Antibodies Directed Against Amyloid Beta Peptide and Compositions Thereof |
| 02/17/2011 | US20110038860 Methods for inhibition of polyclonal b cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking cd1-mediated interactions |
| 02/17/2011 | US20110038859 Methods for the treatment of il-1beta related diseases |
| 02/17/2011 | US20110038858 Methods of treating hematologic cancers using pnp inhibitors such as forodesine in combination with alkylating agents or anti-cd20 agents |
| 02/17/2011 | US20110038857 Novel aza-bicyclic compounds and their use as stimulators of soluble guanylate cyclase |
| 02/17/2011 | US20110038856 Methods of treating neoplastic, autoimmune and inflammatory diseases |
| 02/17/2011 | US20110038855 Trail and methods of modulating t cell activity and adaptive immune responses using trail |
| 02/17/2011 | US20110038854 Strategy for homo- or hetero-dimerization of various proteins in solution and in cell |
| 02/17/2011 | US20110038853 Use of Kif13A and AP-1 Inhibitors for Inhibiting Melanogenesis |
| 02/17/2011 | US20110038852 Antivirals that target transporters, carriers, and ion channels |
| 02/17/2011 | US20110038851 Treatment of synucleinopathies |
| 02/17/2011 | US20110038850 G Protein-Coupled Receptor and Modulators Thereof For The Treatment of Gaba-Related Neurological Disorders Including Sleep-Related Disorders |
| 02/17/2011 | US20110038849 Inhibitory polynucleotide compositions and methods for treating cancer |
| 02/17/2011 | US20110038835 Anilides and analogs as rho kinase inhibitors |
| 02/17/2011 | US20110038832 Method for treatment of macular degeneration using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
| 02/17/2011 | US20110038831 Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
| 02/17/2011 | US20110038791 Methods for inhibiting six1 and eya proteins |
| 02/17/2011 | US20110038790 Treatment and prophylaxis of amyloidosis |
| 02/17/2011 | CA2771105A1 Compositions and methods for the therapy and diagnosis of influenza |
| 02/17/2011 | CA2770915A1 Use of mycobacterium bovis bcg killed by extended freeze drying (efd) for preventing or treating atherosclerosis |
| 02/17/2011 | CA2770790A1 Vaccine having a peptide adjuvant for eliciting a specific immune response to treat viral infection and other conditions |
| 02/17/2011 | CA2770771A1 Monoclonal antibodies for pbp2-a protein and homologous sequences for treatment of infections and immunodiagnosis on bacteria from phylum firmicutes |
| 02/17/2011 | CA2770737A1 Antibodies against human respiratory syncytial virus (rsv) and methods of use |
| 02/17/2011 | CA2770570A1 Immunomodulatory compositions comprising a polymer matrix and an oil phase |
| 02/17/2011 | CA2769929A1 Ophthalmic drug delivery system containing phospholipid and cholesterol |
| 02/17/2011 | CA2769822A1 Methods of modulating immune function |
| 02/17/2011 | CA2769674A1 Combination therapy of an afucosylated cd20 antibody with bendamustine |
| 02/17/2011 | CA2769595A1 Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone |
| 02/17/2011 | CA2769394A1 Human monoclonal antibody against s. aureus derived alpha-toxin and its use in treating or preventing abscess formation |
| 02/16/2011 | EP2284274A1 Expression of protective antigens in transgenic chloroplasts and the production of improved vaccines |
| 02/16/2011 | EP2284257A1 Mycobacteria expressing a cap-specific mannosyl transferase |
| 02/16/2011 | EP2284194A1 Antibodies directed to angiopoietin-2 and uses thereof |
| 02/16/2011 | EP2284193A1 Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation |
| 02/16/2011 | EP2284192A2 Camelidae antibodies for sublingual administration |
| 02/16/2011 | EP2284190A2 Transfer factor from birds eggs |
| 02/16/2011 | EP2284186A1 Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis |
| 02/16/2011 | EP2284183A1 Nucleic acids and proteins from streptococcus groups A and B |
| 02/16/2011 | EP2284182A1 Nucleic acids and proteins from streptococcus groups A and B |
| 02/16/2011 | EP2284181A1 Nucleic acids and proteins from streptococcus groups A and B |
| 02/16/2011 | EP2283869A2 Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in the treatment of viral infections and cancer |
| 02/16/2011 | EP2283868A2 Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in the treatment of viral infections and cancer |
| 02/16/2011 | EP2283867A2 Methods of treatment using anti-ERBB antibody-maytansinoid conjugates |
| 02/16/2011 | EP2283866A2 Methods of treatment using anti-ERBB antibody-maytansinoid conjugates |
| 02/16/2011 | EP2283862A1 Antitumor agent |
| 02/16/2011 | EP2283861A2 Method for Treating Thrombocytopenia with Monoclonal IVIG |
| 02/16/2011 | EP2283860A2 Use for interleukin-33 (il-33) and the il-33 receptor complex |
| 02/16/2011 | EP2283859A2 Pantropic canine coronavirus |
| 02/16/2011 | EP2283858A2 West Nile Vaccine |
| 02/16/2011 | EP2283857A1 Vaccine composition comprising conjugated native N. Meningitidis capsular polysaccharides |
| 02/16/2011 | EP2283855A2 Polypeptides et polynucleotides de phorphorymonas gingivalis |
| 02/16/2011 | EP2283854A2 Porphorymonas gingivalis polypeptides and polynucleotides |
| 02/16/2011 | EP2283853A2 Porphorymonas gingivalis polypeptides and polynucleotides |
| 02/16/2011 | EP2283852A2 Porphorymonas gingivalis polypeptides and polynucleotides |
| 02/16/2011 | EP2283847A2 Disease therapy using dying or dead cells |
| 02/16/2011 | EP2283831A2 Biomakers for pre-selection of patients for anti-IGF1R therapy |
| 02/16/2011 | EP2283815A1 Propellant-free non polar buccal spray of a sedative |
| 02/16/2011 | EP2283814A1 Polar buccal spray of a sedative |
| 02/16/2011 | EP2283813A1 Propellant-free polar buccal spray of a sedative |
| 02/16/2011 | EP2283810A1 Orally administered bacteria as vehicles for systemic delivery of agents |
| 02/16/2011 | EP2283112A1 Compositions comprising prfa*mutant listeria and methods of use thereof |
| 02/16/2011 | EP2283042A2 Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen, conjugates and uses thereof |
| 02/16/2011 | EP2283035A2 Leishmania vaccine using sand fly salivary immunogen |
| 02/16/2011 | EP2283031A2 Lyme disease vaccine |
| 02/16/2011 | EP2282774A1 Sub-region of a plasmodium protein with improved vaccine potential, and medical uses thereof |
| 02/16/2011 | EP2282773A2 Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| 02/16/2011 | EP2282772A1 Compositions and methods to enhance the immune system. |
| 02/16/2011 | EP2282771A1 Nanoparticles for use in pharmaceutical compositions |
| 02/16/2011 | EP2282770A2 Antibodies with altered binding to fcrn and methods of using same |
| 02/16/2011 | EP2282758A2 Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders |
| 02/16/2011 | EP2282755A1 Inhibition of angiogenesis |
| 02/16/2011 | EP2282739A2 Sequential administration of chemotherapeutic agents for treatment of cancer |
| 02/16/2011 | EP2282718A2 Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration |
| 02/16/2011 | EP1962891B1 Dna vaccine for cancer therapy |
| 02/16/2011 | EP1651263B9 Safe mutant viral vaccines |
| 02/16/2011 | EP1545609B1 Antibodies directed against oxidised apolipoprotein B |
| 02/16/2011 | EP1222854B1 Prevention and treatment of diseases associated with blood coagulation |
| 02/16/2011 | CN1946420B Immunising against meningococcal serogroup y using proteins |
| 02/16/2011 | CN101978066A Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin |
| 02/16/2011 | CN101978054A Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor |
| 02/16/2011 | CN101977935A Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
| 02/16/2011 | CN101977930A Vaccine comprising a ribosomal protein extract (rpe) and optionally a th1-promoting adjuvant |
| 02/16/2011 | CN101977929A Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies |
| 02/16/2011 | CN101977927A Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto |
| 02/16/2011 | CN101977926A Mutant forms of streptolysin o |
| 02/16/2011 | CN101977627A Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase |
| 02/16/2011 | CN101977623A Use of therapeutic peptides for the treatment and prevention of cancer |